source
- Roche reports phase 3 success for sefaxersen in IgA nephropathy, eyes accelerated approvalRoche announced that its experimental drug sefaxersen met the primary endpoint in a phase 3 trial for IgA nephropathy, showing reduced proteinuria versus placebo. The interim analysis at week 37 d…
- FDA panel questions effectiveness of Grail's early-cancer detection testFDA's Molecular and Clinical Genetics Panel and agency officials raised concerns about Grail's next-generation sequencing test designed to detect multiple cancers early in adults over 50. The advi…